TEC Says More Evidence Is Required To Judge AMD Combination Therapies
This article was originally published in The Gray Sheet
Executive Summary
More data are needed before healthcare experts can assess the potential benefits of combining new drugs with photodynamic therapy to treat age-related macular degeneration (AMD), according to BlueCross BlueShield Association's Technology Evaluation Center